UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

MEDICINE TO GO PHARMACIES, INC., on behalf of plaintiff and the class members defined herein,

Plaintiff,

Case No.: 2:16-cv-07717-CCC-MF

vs.

MACOVEN PHARMACEUTICALS, LLC, PERNIX THERAPEUTICS HOLDINGS, INC. and JOHN DOES 1-10,

Defendants/Third-Party Plaintiffs.

vs.

ODYSSEY SERVICES, INC.,
Third-Party Defendant.

FOURTH REVISED SCHEDULING ORDER

THIS MATTER having come before the Court on Plaintiff's application for a Fourth Revised Scheduling Order amending the Initial Scheduling Order (DE15) and the Revised Scheduling Order (DE55), and for good cause shown:

IT IS on this day of March, 2018

ORDERED THAT the Court's Initial Scheduling Order (DE15) and the Revised Scheduling Order (DE34) are revised as follows:

1. Fact discovery is extended through March 30, 2018, for the limited purpose of permitting Plaintiff leave to take the deposition of Third-Party Defendant, Odyssey Services, Inc.

2. All other deadlines and provisions in the Court's Initial Scheduling Order (DE 15) and the Revised Scheduling Order (DE5) not addressed above remain unchanged.

HON. MARK FALK, U.S.M.J.